GlobeNewswire by notified

Global Bioenergies: strong progress in first half 2023

Share

PRESS RELEASE

Global Bioenergies: strong progress in first half 2023

First half revenue of €3.1 million

Reduction of net loss

ASTM certification obtained for Sustainable Aviation Fuel technology

Upsizing of plant project

Evry, 19September 2023 – 05:45 p.m.: Global Bioenergies’ Board of Directors held on 15 September approved the H1 2023 financial statements, which have been audited by the Statutory Auditor and show revenue of €3.1 million.

Samuel Dubruque, Chief Financial Officer of Global Bioenergies, said: “This record revenue since the creation of the Company, has enabled us to significantly reduce our net loss: (€4.1) million in H1 2023 compared to (€5.8) million in H1 2022 and (€7.6) million in H1 2021. Isonaturane™ 12 sales illustrate both the market appetite for our products and our ability to produce in compliance with the most stringent regulatory standards.”

Marc Delcourt, co-founder and CEO of Global Bioenergies, added: “The first half of 2023 was also marked by the achievement of the ASTM certification for our sustainable aviation fuel technology. This certification, an essential gateway reserved for a limited range of technologies, gives us access to the market for Sustainable Aviation Fuel, which is the main decarbonisation option for air transport. Thanks to the larger scale of operation of our process and the reduction in production costs, we plan to start operating in the European SAF market by 2030, when the mandatory minimum share of sustainable aviation fuels are raised from 2% to 6% in the European Union.”

Group Profit & Loss Account

€ thousandsfrom 01/01/23
to 30/06/23
6 months
from 01/01/22
to 30/06/22
6 months
from 01/01/21
to 30/06/21
6 months
Operating income7,3261,0591,903
Operating expenses11,2646,6329,455
Operating profit (loss)-3,938-5,573-7,552
EBITDA-3,026-5,014-6,515
Financial profit (loss)23-61-79
Exceptional profit (loss)-169-12410
Income tax---
Net profit (loss)-4,084-5,759-7,621


€ thousandsfrom 01/01/23
to 30/06/23
from 01/01/22
to 30/06/22
from 01/01/21
to 30/06/21
Operating income7,3261,0591,903
Revenue3,10214433
Operating subsidies1,1848941,331
Change in inventory of finished products1,917-34527
Other income1,1235512

Operating income mainly consists of revenue from the first sale of several tonnes of IsonaturaneTM 12.

€ thousandsfrom 01/01/23
to 30/06/23
from 01/01/22
to 30/06/22
from 01/01/21
to 30/06/21
Operating expenses11,2646,6329,455
Staff costs2,1942,3092,079
Average number of employees (No.)47.647.341.2
Industrialisation expenses2,6872,5974,886
Change in IBN & derivatives inventories2,461-584- 520
Laboratory costs192185322
Rent, servicing & maintenance518423413
Intellectual property186137326
Depreciation, amortisation and provisions2,0285591,038
Other structural costs9971,006911

Total isobutene and derivatives inventory entries, which impact both operating income and operating expenses, result in a total expense of €0.7 million in H1 2023.

Excluding these inventory entries, operating expenses increased €0.6 million versus H1 2022, mainly due to the increase in depreciation charges resulting from the commissioning of the Pomacle production unit on 1 November 2022. Other expense items remained stable.

Group Balance Sheet

Assets(€ thousands)30/06/2331/12/2231/12/21Passif(k€)30/06/2331/12/2231/12/21
Intangible assets411539800Capital905749743
Tangible assests3,0603,612637Share premium10,45216,02929,289
Assets under construction1294011,897Balance carried forward-2,769-2,708-4,697
Financial assets8291,5461,544Profit (loss)-4,084-11,986-11,773
Equipment subsidy379463-
NON CURRENT ASSETS4,4286,0974,879EQUITY4,8832,54713,562
IBN and derivatives inventories1,6042,3421,793PROVISIONS5811061
Consumables inventories298250250
Receivables4,8473,6473,524Conditional advances and loans10,98511,48612,454
Cash9,8558,76820,931Trade payables4,2295,5803,520
Marketable securities176173147Tax and social security liabilities7255021,185
Prepaid expenses387300261Other debts and deferred income7131,3521,003
CURRENT ASSETS17,16715,48026,907PAYABLES16,65318,92118,163
TOTAL ASSETS21,59521,57731,785TOTAL LIABILITIES21,59521,57731,785

The reduction in fixed assets is due to (i) the depreciation of the Pomacle-Bazancourt production unit commissioned at the end of 2022, (ii) the repayment of the guarantee at the end of one of the subsidy projects and (iii) the impairment of capitalised expenses specifically related to the 2,000 ton plant project.

Inventories decreased and receivables increased following delivery and invoicing of the first tonnes of IsonaturaneTM 12 at the end of the first half.

The cash balance increased by €1.1 million in the first half. Capital increases generated a net inflow of €6.5 million, supplemented by the receipt of subsidies and trade receivables (€2.7 million). Cash flows from operating activities accounted for most of the cash outflows over the period (€7.7 million) and were heavily impacted by IsonaturaneTM 12 production costs.

Highlights of the first half of 2023, recent events and outlook

-Successful delivery of the first tons of IsonaturaneTM 12

To meet orders placed by major cosmetics companies including L’Oréal, Global Bioenergies has set up a dedicated value chain, partly subcontracted, and delivered several tonnes of IsonaturaneTM 12 in H1 2023. Although the associated revenue is substantial, the corresponding production costs remain considerably high and this business activity, which will not generate a significant margin for the Company, is now no longer a priority. The Company is currently focusing all its efforts on building a larger plant.

-ASTM certification for sustainable aviation fuel from Global Bioenergies technology

The aviation industry requires all of its fuels to be certified by ASTM. Sustainable aviation fuels (SAF) are certified worldwide in accordance with the ASTM D7566 standard, which sets out the fuel specification requirements and maximum blending percentage with conventional fuels. The standard allows SAFs to be considered as “drop-in” fuels, meaning that they can be blended up to 50% with fossil kerosene and can be safely used in airliners and existing infrastructure worldwide.

Global Bioenergies obtained certification for its process in June 2023 marking the starting point for the roll-out of its sustainable aviation fuel technology. In order to become a major player in this field, production costs still need to be reduced significantly in order to be compatible with market prices. The Company aims for a share of the European SAF market in 2030, when the mandatory minimum share of sustainable aviation fuels will be raised to 6% in Europe.

  • Focus on the larger scale plant project

Global Bioenergies has decided to adjust its roadmap to focus as of now on building a large-scale plant capable of producing up to 10,000 tonnes of isobutene and derivatives per year. This increase in production volume coupled with a reduction in selling prices will enable the Company to meet the needs of the cosmetics market more broadly and then gradually penetrate the Sustainable Aviation Fuel market. The plant would start operations at the end of 2027. Global Bioenergies will release design and construction schedules by the end of 2023.

About GLOBAL BIOENERGIES

Global Bioenergies substitutes products of fossil origin with products of natural origin. In their quest for naturalness without compromising on performance, the cosmetics players are the Company's first customers. By 2027, the Company will be operating its innovative process in a large-scale plant. By 2030, the Company plans to become a leader in the huge emerging market for sustainable aviation fuels, in order to fight against global warming. Global Bioenergies is listed on Euronext Growth in Paris (FR0011052257 - ALGBE). L'Oréal is its largest shareholder, with a 13.5% stake.

Contacts

GLOBAL BIOENERGIES
+33 (0)1 64 98 20 50
invest@global-bioenergies.com



Follow our news



Receive information about Global Bioenergies directly by subscribing to our news feed on https://www.global-bioenergies.com/inscription-newsletter/





Follow us on LinkedIn:
Global Bioenergies





NewCapInvestor relations

Louis-Victor Delouvrier
Quentin Massé
globalbioenergies@newcap.eu

+33 (0)1 44 71 94 94





NewCap – Media relations



Nicolas Merigeau
globalbioenergies@newcap.eu
+33 (0)1 44 71 94 98

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

LeddarTech and Prospector Capital Corp. Announce Effectiveness of Registration Statement and December 13, 2023 Extraordinary General Meeting to Approve Business Combination4.12.2023 23:30:00 CET | Press release

QUEBEC CITY, Dec. 04, 2023 (GLOBE NEWSWIRE) -- LeddarTech Inc.® (“LeddarTech” or the “Company”), an automotive software company that provides patented disruptive AI-based low-level sensor fusion and perception software technology for ADAS and AD, and Prospector Capital Corp. (“Prospector”) (NASDAQ: PRSR, PRSRU, PRSRW), a publicly traded special-purpose acquisition company led by former Qualcomm President Derek Aberle and chaired by former Qualcomm Vice Chairman Steve Altman, today announced that on December 4, 2023 the U.S. Securities and Exchange Commission (the “SEC”) declared effective the Registration Statement on Form F-4, as amended, filed by LeddarTech Holdings Inc. (“Newco”) in connection with the previously announced proposed business combination (the “Business Combination”). The filing can be viewed in its entirety on the SEC’s website at www.sec.gov. Prospector also commenced mailing the definitive proxy statement/prospectus on December 4, 2023, which was included in the Reg

Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 20234.12.2023 22:30:00 CET | Press release

Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights11/30/2023 96,431,770 Total gross of voting rights: 96,431,770 Total net* of voting rights: 96,186,256 * Net total = total number of voting rights attached to shares – shares without voting rights Attachment PDF Version

Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.4.12.2023 22:16:59 CET | Press release

Aggregate gross proceeds of approximately €50.9 million (equivalent to approximately $53.8 million) received by NANOBIOTIX has increased to approximately €55.5 million (equivalent to approximately $58.7 million) extending its runway into mid’ 2025 PARIS and CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces today the closing of the previously announced subscription by Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”) for 901,256 additional ordinary shares of the Company, in the form of restricted American Depositary Shares (“ADSs”), for an aggregate amount of $4.8 million, equivalent to €4.6 million1 (the “Remaining Placement Amount”, and the subscription transaction being the “Remaining Placement”), following the approval by the French Ministry of Economy of JJ

Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH4.12.2023 22:05:00 CET | Press release

The DMC recommended to continue the clinical trial without modification of the protocol, based on the pre-planned review of safety dataThe safety assessment was based on the review of safety data from more than 500 patients, including patients that have been treated with lanifibranor for more than 72 weeksThe DMC review remains consistent, confirming the good safety profile of lanifibranor Daix (France), Long Island City (New York, United States), December 4, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced the positive recommendation from the third meeting of the Data Monitoring Committee (DMC) to continue the NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH without modification to the trial protocol. The DMC

Standard Lithium to Participate in December Investor Conferences4.12.2023 22:04:35 CET | Press release

VANCOUVER, British Columbia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium development company, today announced its participation in the following virtual December investor conferences: Event:Deustche Bank 8th Annual Virtual Lithium Battery Supply Chain ConferenceDate:December 6, 2023Panel:US Based Lithium Supply, featuring Robert Mintak, CEO and Director of Standard Lithium, 7:45am – 8:15am PTEvent:Bank of America Securities Virtual 2023 Lithium and Battery Storage ConferenceDate:December 7, 2023Panel:Company Presentation, featuring Robert Mintak, CEO and Director of Standard Lithium, 7:45am – 8:30am PT Management will be hosting one-on-one meetings during the conferences. Interested investors should contact their Deutsche Bank or Bank of America representative or Standard Lithium Investor Relations at investors@standardlithium.com. About Standard Lithium Ltd. St